- Home
- RIV vs SLN Comparison
RIV vs SLN Comparison
Compare RIV & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- SLN
- Stock Information
- Founded
- RIV 2015
- SLN 1994
- Country
- RIV United States
- SLN United Kingdom
- Employees
- RIV N/A
- SLN N/A
- Industry
- RIV Finance Companies
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- RIV Finance
- SLN Health Care
- Exchange
- RIV Nasdaq
- SLN Nasdaq
- Market Cap
- RIV 266.0M
- SLN 227.2M
- IPO Year
- RIV N/A
- SLN N/A
- Fundamental
- Price
- RIV $12.45
- SLN $5.54
- Analyst Decision
- RIV
- SLN Buy
- Analyst Count
- RIV 0
- SLN 5
- Target Price
- RIV N/A
- SLN $32.60
- AVG Volume (30 Days)
- RIV 87.6K
- SLN 54.4K
- Earning Date
- RIV 01-01-0001
- SLN 08-07-2025
- Dividend Yield
- RIV 12.85%
- SLN N/A
- EPS Growth
- RIV N/A
- SLN N/A
- EPS
- RIV N/A
- SLN N/A
- Revenue
- RIV N/A
- SLN $27,169,000.00
- Revenue This Year
- RIV N/A
- SLN N/A
- Revenue Next Year
- RIV N/A
- SLN N/A
- P/E Ratio
- RIV N/A
- SLN N/A
- Revenue Growth
- RIV N/A
- SLN 22.28
- 52 Week Low
- RIV $9.63
- SLN $1.97
- 52 Week High
- RIV $12.43
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- RIV 54.58
- SLN 52.13
- Support Level
- RIV $12.40
- SLN $4.77
- Resistance Level
- RIV $12.56
- SLN $5.29
- Average True Range (ATR)
- RIV 0.10
- SLN 0.38
- MACD
- RIV -0.00
- SLN 0.05
- Stochastic Oscillator
- RIV 52.73
- SLN 79.14
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.